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Introduction and aims 
Cyclodextrins (CDs) are a family of water soluble, biocompatible and biodegradable 
oligosaccharides known to improve the solubility, stability and bioavailability of many drugs. 
 
Marie Curie Project CYCLON, composed of research groups from seven European countries, 
was assembled in order to develop, through the training of young researchers within a 
highly competent and multidisciplinary network, a new generation of multifunctional drug 
nanocarriers based on CDs. 
These nano-platforms can help in accessing specific biological targets, in controlling the 
release of therapeutic compounds, in enhancing the in vivo efficiency of several drugs, in 
increasing the drug loading capacity and in providing multifunctionalization of a therapy. 
 
CycloLab as the Hungarian participant in CYCLON project has almost 40-year experience in 
the preparation of various CD derivatives. As a PhD student I have developed new synthetic 
strategies and prepared novel derivatives based on this experience. Within the CYCLON 
project I had the possibility to work 3 and 4 months at the University of Almeria, Spain and at 
the University of Catania, Italy, where I took part in the research on biological targeting 
strategies as well as in photochemical studies, respectively.  
 
During the three-years collaboration my role was to achieve the followings: 
1) To synthesize novel biodegradable and biocompatible CD derivatives to be further applied 
for the elaboration of nanocarriers. 
2) To create new CD derivatives labeled with fluorescent moieties for physico-chemical and 
in-vitro biological studies including photodynamic therapy applications. 
3) To develop the syntheses of scaled up quantities of well characterized, industrially purified, 
key-intermediates in CD chemistry for further modifications. 
4) To implement synthetic strategies in order to obtain amphiphilic and charged CDs and to 
build a library of compounds based on one-pot synthesis scheme. 
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Experimental Part 
The synthetic work was divided in two fundamental parts: 
a) Scale-up of the common intermediates 
The first part of my work consisted in the scaling-up of suitable key intermediates to be 
fluorescent tagged. In order to obtain CD scaffolds with different physico-chemical and 
functional properties (charge, solubility, complexing capacity, biocompatibility, etc.) the 
following versatile procedure was followed (Fig. 1). 
The 6-monoazido βCD derivative is the key precursor of almost all the CD-scaffolds. 
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Fig.1. Scheme of the nine CD-scaffolds with the corresponding maximum batch size 
I decided to randomly alkylate the starting 6-monoazido βCD in order to obtain the 2-
hydroxypropyl, the methyl and the carboxymethyl 6-monoazido βCDs. The statistical 
alkylation of the 6-monoazido βCD yields products that can serve as a “library” for many 
different guests. This means that each of the obtained scaffolds is a mixture of structural 
isomers providing slightly different binding sites for the guest molecules, which can find, as 
in a library, the most suitable host molecule in this mixture. 
b) Fluorescent labeling  
Native CDs are UV/Vis spectroscopically inert, but they can be converted into 
spectroscopically active compounds by modification with a chromophore unit. Among the 
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chromophores the ones that guarantee the highest detection sensitivity and can ensure a very 
high resolution in the imaging process is the group of fluorophores. 
The basic ideas for the fluorescent modification were the synthesis of CD intermediates 
possessing a single functional group to be exclusively dedicated for the labeling (azido-, 
amino group, see Fig. 1) and the choice of a synthetic strategy thus allowing the insertion of a 
single moiety of fluorophore per CD ring. At the same time, the “labeling-dedicated” 
functional group had to be versatile enough to allow further modifications of the CD scaffold 
by preserving the possibility of anchoring the fluorophore. According to this strategy, I 
synthesized, purified and characterized a series of rhodamine- and fluorescein-labeled CDs 
(Fig. 2). 
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Fig.2. Scheme of rhodamine- and fluorescein-labeled CDs  
The synthesis of the third series of fluorescent βCD derivatives, the nitrobenzofurazan-labeled 
CDs, was based on two different approaches. The first procedure relied on the nucleophilic 
substitution between 4-chloro-7-nitrobenzofurazan and the amino-βCD scaffolds (Fig. 3). 
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Fig.3. Scheme of nitrobenzofurazan-labeled CDs, first strategy 
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The second strategy dealt with azide-alkyne Huigens cycloaddition between the azido-βCD 
scaffolds and a propargylated derivative of the nitrobenzofurazan (Fig. 4). 
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Fig.4. Scheme of nitrobenzofurazan-labeled CDs, second strategy 
The introduction into fluorescent CD derivatives of phosphate groups which are ionized at 
physiological pH, can modify (increase) the water solubility of these compounds by 
preserving their biocompatibility. 
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Fig.5. Scheme of phosphorylation for fluorescent βCDs 
The strategy for the phosphorylation of the fluorescent CD derivatives was based on a one 
step reaction (Fig. 5). The advantages of this approach are that the introduction of phosphate 
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groups can be accomplished in a one (terminal) step and that the reaction can be easily 
reproduced and scaled-up. 
 
The new findings of my research 
1) I have built-up a library made of fourteen of fluorescent βCD derivatives. All the 
compounds were characterized by suitable chromatographic and spectroscopic 
techniques (TLC, HPLC, NMR) and their purity was checked by capillary 
electrophoresis. I synthesized original fluorescent molecules using fluoresceinyl, 
rhodaminyl, nitrobenzofurazanyl functions built-up on various CD scaffolds, such as 
hydroxypropyl, randomly methyl, carboxymethyl βCDs, thus creating fluorescent 
amphiphilic and charged CDs that can be exciting tools for basic and applied research 
as well as multifunctional nanocarriers in photodynamic therapy. 
2) I have worked out general synthetic strategies useful for the preparation of various 
monofunctionalized CD derivatives based on the randomly alkylation of 6-
monosubstituted CD derivatives. 
3) I have synthesized and characterized phosphorylated-βCD derivatives, together with 
their fluorescent analogues. These derivatives are able to interact in a controlled way 
with cationic architectures such as nano-metal-organic framework (MOF). The 
promising results that could be achieved resulted in the joined patent CNRS/CycloLab. 
4) Joining the research group at the University of Catania I have participated in the 
development of nanocarriers useful for photoactivated nitric oxide releasing 
compounds. 
5) The rhodamine-labeled CD derivatives prepared by me can indicate the presence of 
the anticancer drug topotecan due to the energy transfer between the two molecules. 
7) The fluorescein-labeled CD derivatives are excellent tools for biological imaging. 
8) The nitrobenzofurazan-labeled CD derivatives can act as nanocarriers for new 
photosensitizers. 
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Conclusions  
I have synthesized novel CD derivatives to be further applied for the elaboration of 
nanocarriers. 
I developed the scaled-up synthesis of the following intermediates: 6-monotosyl-βCD, 6-
monoazido-βCD, -HPβCD, -RAMEB, -CMβCD and 6-monoamino- βCD. -HPβCD, -
RAMEB, -CMβCD in 10-300 g scale. 
I have worked out the synthesis and prepared new CD derivatives labeled with fluorescent 
moieties by appending the fluorophore via a stable thioureido group. The applications of 
these materials span from the biological field and material science to the pure physico-
chemical investigations. 
By implementing the synthetic strategies I have built a library of compounds. The library 
of the fluorescent CD derivatives synthesized in my PhD work consists of 5 CD scaffolds 
with 3 fluorescent moieties. The strategy I worked out for the synthesis was summarized 
for the rhodaminyl derivatives in publication No. 4. This strategy can be easily adapted for 
further CD scaffolds including α- and γ-CD derivatives, also their polymers, with various 
functionalities (the same or different applied in my work) as well as further fluorescent 
moieties.  
The fluorescent CD derivatives are now on the fine chemicals list of CycloLab creating a 
new product line for the company. 
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